Drinabant is primarily investigated for its potential in treating obesity and related metabolic disorders due to its action as a cannabinoid receptor type 1 (CB1) antagonist. By blocking CB1 receptors in the central nervous system and peripheral tissues, it helps regulate appetite and energy balance, leading to reduced food intake and weight loss. It has also shown promise in improving lipid profiles and insulin sensitivity, suggesting benefits in managing dyslipidemia and type 2 diabetes. Additionally, research explores its use in substance abuse disorders, particularly in reducing cravings and relapse in nicotine and alcohol dependence. However, due to concerns over psychiatric side effects linked to central CB1 blockade, development has focused on peripherally acting analogs to maintain efficacy with improved safety.